Accelerated arteriosclerosis: A form of transplant arteriopathy

Current Opinion in Organ Transplantation

Volumn 15, Issue 1, 2010, Pages 11-15

  Hill, Gary S ^a   Nochy, Dominique ^a   Loupy, Alexandre ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Antibody mediated rejection; Arteriosclerosis; Transplant arteriopathy; Transplantation

Indexed keywords

ADAM PROTEIN; CELL ANTIBODY; COLLAGEN; CYTOKINE; DONOR SPECIFIC ANTIBODY; ENDOTHELIN 1; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; LEUKOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANTIBODY MEDIATED REJECTION; ARTERIOSCLEROSIS; ARTERY DISEASE; ARTERY LESION; CELL MEDIATED REJECTION; DONOR; ELASTIC FIBER; ENDARTERITIS; EXTRACELLULAR MATRIX; GRAFT REJECTION; HUMAN; INTIMA; LEUKOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MYOFIBROBLAST; REVIEW; T LYMPHOCYTE; TRANSPLANT ARTERIOPATHY; TRANSPLANT ARTERIOSCLEROSIS; TRANSPLANT ATHEROSCLEROSIS; TRANSPLANTATION;

ANIMALS; ANTIBODIES; ARTERIOSCLEROSIS; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; KIDNEY TRANSPLANTATION; RENAL ARTERY; TERMINOLOGY AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 75749093483     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283342684     Document Type: Review

References (56)

1. Coupel S, Leboeuf F, Boulday G, et al. RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy. J Am Soc Nephrol 2004; 15:2429-2439.
2. Jin YP, Jindra PT, Gong KW, et al. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 2005; 79:S19-S21.
3. Yamada K, Hatakeyama E, Sakamaki T, et al. Involvement of platelet-derived growth factor and histocompatibility of DRB 1 in chronic renal allograft nephropathy. Transplantation 2001; 71:936-941.
4. Gerbase-DeLima M, Campos EF, Tedesco-Silva H, et al. Anti-HLA class II antibodies and chronic allograft nephropathy. Clin Transpl 2006:201-205.
5. Bian H, Harris PE, Reed EF. Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation. Int Immunol 1998; 10:1315-1323.
6. Harris PE, Bian H, Reed EF. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol 1997; 159:5697-5704.
7. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18:1046-1056.
8. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3:189-220.
9. Colvin RB. Renal transplant pathology. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's pathology of the kidney. 6th ed. Philadelphia: Lippincott, Williams & Wilkins; 2007. pp. 1347-1490.
10. Mengel M, Gwinner W, Schwarz A, et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007; 7:356-365.
11. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708-714.
12. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody: analysis using the Banff grading schema. Transplantation 1996; 61:1586-1592.
13. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donorspecific antibodies. Am J Transplant 2009; 9:1-10.
14. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7:832-841.
15. Nickeleit V, Vamvakas EC, Pascual M, et al. The prognostic significance of specific arterial lesions in acute renal allograft rejection. J Am Soc Nephrol 1998; 9:1301-1308.
16. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713-723. (Pubitemid 29082898)
17. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of MHC class II antigens in normal human organs. Transplantation 1984; 38:293-298.
18. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984; 38:287-292.
19. Bian H, Reed EF. Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. J Immunol 1999; 163:1010-1018.
20. Jin YP, Fishbein MC, Said JW, et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004; 65:291-302.
21. Bieri M, Oroszlan M, Farkas A, et al. Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability. Int J Biochem Cell Biol 2009.
22. Arnold ML, Pei R, Spriewald B, Wassmuth R. Anti-HLA class II antibodies in kidney retransplant patients. Tissue Antigens 2005; 65:370-378.
23. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7:857-863.
24. Le Bas-Bernardet S, Hourmant M, Valentin N, et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003; 75:477-482.
25. Campos EF, Tedesco-Silva H, Machado PG, et al. Posttransplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6:2316-2320.
26. Vareesangthip K, Assavisaraporn W, Bintaprasit W, Vejbaesya S. Effect of posttransplant anti-HLA antibody on outcome of renal transplantation. Transplant Proc 2004; 36:2048-2050.
27. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to antihuman leukocyte antigen class II antibody levels. Transplantation 2008; 86:681-685.
28. Ferry BL, Welsh KI, Dunn MJ, et al. Anticell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol 1997; 5:17-24.
29. Le Bas-Bernardet S, Hourmant M, Coupel S, et al. Non-HLA-type endothelial cell reactive alloantibodies in pretransplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003; 3:167-177.
30. Wu GD, Jin YS, Salazar R, et al. Vascular endothelial cell apoptosis induced by antidonor non-MHC antibodies: a possible injury pathway contributing to chronic allograft rejection. J Heart Lung Transplant 2002; 21:1174-1187.
31. Zou Y, Stastny P, Susal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357:1293-1300.
32. Panigrahi A, Gupta N, Siddiqui JA, et al. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Hum Immunol 2007; 68:362-367.
33. Sumitran-Holgersson S. Relevance of MICA and other non-HLA antibodies in clinical transplantation. Curr Opin Immunol 2008; 20:607-613.
34. Stastny P, Zou Y, Fan Y, et al. The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells. Contrib Nephrol 2009; 162:99-106.
35. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569.
36. Tanabe S, Nakatani T, Han Y, et al. Enhanced expression of angiotensin II type 1 receptor in the neointima of transplant renal arteriosclerosis in human renal allografts. Transplant Proc 2001; 33:1172-1174.
37. Matsuo K, Takebayashi S. Ultrastructure of microcirculation in renal grafts in patients with acute or chronic rejections. Acta Pathol Jpn 1985; 35:1123-1134.
38. Kennedy LJ Jr, Weissman IL. Dual origin of intimal cells in cardiac-allograft arteriosclerosis. N Engl J Med 1971; 285:884-887.
39. Grimm PC, Nickerson P, Jeffery J, et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 2001; 345:93-97.
40. Geraghty JG, Stoltenberg RL, Sollinger HW, Hullett DA. Vascular smooth muscle cells and neointimal hyperplasia in chronic transplant rejection. Transplantation 1996; 62:502-509.
41. Floege J, Hudkins KL, Davis CL, et al. Expression of PDGF alpha-receptor in renal arteriosclerosis and rejecting renal transplants. J Am Soc Nephrol 1998; 9:211-223.
42. Gould VE, Martinez-Lacabe V, Virtanen I, et al. Differential distribution of tenascin and cellular fibronectins in acute and chronic renal allograft rejection. Lab Invest 1992; 67:71-79.
43. Simonson MS, Emancipator SN, Knauss T, Hricik DE. Elevated neointimal endothelin-1 in transplantation-associated arteriosclerosis of renal allograft recipients. Kidney Int 1998; 54:960-971.
44. Deng DX, Jiang J, Garcia B, et al. Endothelin-1, endothelin-3 and their receptors (endothelin(A) and endothelin(B)) in chronic renal transplant rejection in rats. Transpl Int 2000; 13:175-182.
45. Nakatani T, Tanabe S, Han YS, et al. Enhanced expression of endothelin-A receptor in human transplant renal arteriosclerosis. Int J Mol Med 2003; 11:153-156.
46. Tanabe S, Ueda M, Han YS, et al. Up-regulation of endothelin-converting enzyme during the development of transplant renal arteriosclerosis in human renal allografts. Transplant Proc 1997; 29:1517-1519.
47. Alpers CE, Davis CL, Barr D, et al. Identification of platelet-derived growth factor A and B chains in human renal vascular rejection. Am J Pathol 1996; 148:439-451.
48. Lantz I, Dimeny E, Larsson E, et al. Increased immunoreactivity of transforming growth factor-beta in human kidney transplants. Transpl Immunol 1996; 4:209-214.
49. Horvath LZ, Friess H, Schilling M, et al. Altered expression of transforming growth factor-beta S in chronic renal rejection. Kidney Int 1996; 50:489-498.
50. Kennard S, Liu H, Lilly B. Transforming growth factor-beta (TGF-1) downregulates Notch3 in fibroblasts to promote smooth muscle gene expression. J Biol Chem 2008; 283:1324-1333.
51. Quillard T, Coupel S, Coulon F, et al. Impaired Notch4 activity elicits endothelial cell activation and apoptosis: implication for transplant arteriosclerosis. Arterioscler Thromb Vasc Biol 2008; 28:2258-2265.
52. Canfield AE, Farrington C, Dziobon MD, et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol 2002; 196:228-234.
53. Boulday G, Coupel S, Coulon F, et al. Antigraft antibody-mediated expression of metalloproteinases on endothelial cells. Differential expression of TIMP-1 and ADAM-10 depends on antibody specificity and isotype. Circ Res 2001; 88:430-437.
54. Malyszko J, Malyszko JS, Hryszko T, et al. Renal transplant recipients with coronary artery disease exhibit impairment in fibrinolysis and structural changes in carotid arteries. Transpl Int 2005; 18:256-259.
55. Szabo A, Lutz J, Schleimer K, et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57:982-991.
56. Yi T, Cuchara L, Wang Y, et al. Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of interferongamma. Transplantation 2006; 81:559-566.